Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Nimotuzumab by InnoMab for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Nimotuzumab is under clinical development by InnoMab and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Data Insights
Nimotuzumab by Innogene Kalbiotech for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Nimotuzumab is under clinical development by Innogene Kalbiotech and currently in Phase III for Head And Neck Squamous Cell Carcinoma...